The best drugs only work if they can get where they need to go. Nano RED is developing two novel platforms in parallel to prevent and treat SARS-CoV-2, and to revolutionize cancer immunotherapy through the development of two complementary drug delivery platforms.
Anti-virals of the future
With support from the National Science Foundation, we have developed a new vehicle that prevents SARS-CoV-2 from attacking and entering vulnerable cells in the lungs. At the same time, our novel vehicle delivers a potent cocktail of genomic medicines to at-risk lung cells which prevents the SARS-CoV-2 virus from replicating. We are adapting this same approach to treat influenza, respiratory syncytial virus, and causes of the common cold. This same delivery vehicle can also be repurposed in the fight against lung cancers. This platform promises to be an agile tool that can be easily adapted to prevent and treat future respiratory viral pandemics as they emerge. Read more here.
Cancer Immunotherapy of the future
Nano RED's approach relies on a plug-and-play platform developed at the National Cancer Institute capable of carrying small molecules, high molecular weight proteins and bulky chemotherapeutics and releasing them in activated form directly within the tumor and tumor microenvironment- all at the discretion of a physician in real time who directs drug release. Read more here.